Last updated on January 2020

The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Brief description of study

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Clinical Study Identifier: NCT03659136

Find a site near you

Start Over

Funda o Champalimaud,

Lisboa, Portugal
  Connect »

Hospital Beatriz ngelo

Loures, Portugal
  Connect »